Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Otsuka Holdings Company ADR (OP: OTSKY )

21.56 +0.21 (+1.01%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 75,363
Open 21.75
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 21.34
Today's Range 21.56 - 21.85
52wk Range 16.04 - 22.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
OTSKY Stock Earnings: Otsuka Holdings Reported Results for Q1 2024
Otsuka Holdings just reported results for the first quarter of 2024. 
Via InvestorPlace
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo. 
Via Benzinga

Performance

YTD
+15.79%
+15.79%
1 Month
+2.13%
+2.13%
3 Month
+4.97%
+4.97%
6 Month
+11.54%
+11.54%
1 Year
+18.01%
+18.01%

More News

Read More
Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
Via Benzinga
Regulatory Setback For Medtronic's High Blood Pressure Device - FDA Backed Japanese Firms' Similar Device For Uncontrolled Hypertension
Via Benzinga
Exposures Product Safety
Individuals With Uncontrolled Hypertension - FDA Adcomm Panel Just Supported Japanese MedTech's Blood Pressure Treatment Device
Via Benzinga
Exposures Product Safety
Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study
Via Benzinga
Why Are Akebia Therapeutics Shares Falling Today?
Via Benzinga
FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia
Via Benzinga
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation
Via Benzinga
Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches
Via Benzinga
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Via Benzinga
Has A Sugar Daddy Emerged In The Psychedelic Drug Industry?
Via Talk Markets
4 Pre-Merger SPACs to Buy That Are Poised to Soar
Via InvestorPlace
Topics Electric Vehicles
Exposures Electric Vehicles
Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia
Via Benzinga
Exposures Product Safety
3 Cheap Pharmaceutical Stocks to Grab Now
Via Talk Markets
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.